44 peer-reviewed publications, primarily in oncology: 24 are in journals with an impact factor > 5. My current h-index is 23.
L.C Gilligan, J. Bradbury, A.E Taylor, S. He, D.M O’Neil, M. Viant, P.A Foster. A novel UPLC-MS/MS method to extract and quantify sulphated and non-sulphated oestrogens automatically optimised using MUSCLE software. J Chromatography. In preparation.
L.C. Gilligan, A-M. Hewitt, A. Kupryte, K. Burnell, D. Morton, P.A. Foster. Oestrogen metabolism is dysregulated by TNF-alpha and IL-6 in colorectal adenoma and carcinoma. Carcinogenesis. In preparation.
G. P. Prevost, S Xu, M. Garrido, M. Serova, O.D.E. Vewer, C. Gespach, J-F. Briand, A. Tijeras-Raballand, M. Gutmann, A. Hendrix, M. Sabbah, A. Chachereau, A. de Gramont, N. Neamati, M-H. Pitty, P.A. Foster. XCE853: a novel PDI inhibitor that inhibits proliferation of human tumor cells ex vivo, in vitro and in vivo. Cancer Res. In Preparation
44. P.A. Foster, J.W. Mueller. Insights into steroid sulfation and desulfation pathways. J Mol Endocrinol. 2018;[ePub ahead of print].
43. V. Chortis, A.E. Taylor, C.L. Doig, M.D. Walsh, E. Meimaridou, C. Jenkinson, G. Rodriguez-Blanco, C.L. Ronchi, A. Jafri, L.A. Metherell, D. Hebenstreit, W.B. Dunn, W. Arlt, P.A. Foster. Nicotinamide Nucleotide Transhydrogenase as a novel treatment target in adrenocortical carcinoma. Endocrinol. 2018;[ePub ahead of print]
42. D.A. Gibson, P.A. Foster, I. Simitsidellis, H. Critchley, O. Kelepouri, F. Collins, P.T. Saunders. A role for steroid sulfatase in intracrine regulation of endometrial decidualisation. J Mol Endocrinol. 2018;[ePub ahead of print]
41. W. Dohle, F.L. Jordan, G. Menchon, A.E. Prota, P.A. Foster, P. Mannion, E. Hamel, M.P.Thomas, P.G. Kasprzyk, E. Ferrandis, M.O. Steinmetz, M.P. Leese, B.V.L. Potter. Quinazolinone-based anticancer agents: Synthesisantiproliferative SAR, antitubulin activity, and tubulin co-crystal structure. J Med Chem. 2018;61:1031-1044.
40. E. Meimaridou, M. Goldsworthy, V. Chortis, E. Fragouli, P.A. Foster, W. Arlt, R. Cox, L.A. Metherell. NNT is a key regulator of adreanl redox homeostasis and steroidogenesis in male mice. J Endocrinol. 2018;236:13-28.
39. L.C. Gilligan, H.P. Rahman, A.M. Hewiit, A.J. Sitch, A. Gondal, A. Arvaniti, A.E. Taylor, M.L. Read, D.G. Morton, P.A. Foster. Estrogen activation by steroid sulfatase increases colorectal cancer proliferation via GPER. J Clin Endocrinol Metab. 2017;102:4435-4447.
38. L.C. Gilligan, A. Gondal, V. Tang, M.T. Hussain, A. Arvaniti, A.M. Hewitt, P.A. Foster. Estrone sulfate transport and steroid sulfatase activity in colorectal cancer: Implications for hormone replacement therapy. Front Pharmacol. 2017;8:103.
37. H.P. Rahman, J. Hofland, P.A. Foster. In touch with your feminine side: how oestrogen metabolism impacts prostate cancer. Endocr Relat Cancer. 2016;23:R249-66.
36. M.I. El-Gamal, M.H. Semreen, P.A. Foster, B.V.L. Potter. Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors. Bioorg Med Chem. 2016;24:2762-7.
34. C. Stengal, S.P. Newman, M.P. Leese, B.V.L. Potter, M.J.Reed, A. Purohit, P.A. Foster. The in vitro and in vivo activity of the microtubule disruptor STX140 is mediated by Hif-1 alpha and CAIX expression. Anticancer Res. 2015;35:5249-61.
33. C. Stengal, M.P. Leese, S.P. Newman, M.J. Reed, B.V. Potter, A. Purohit, P.A. Foster. STX2484, a novel tubulin binding agent, is effective against chemoresistant breast cancer. Br. J Cancer. 2014;111:300-8.
32. F. Meyer-Losic, S.P. Newman, J.M. Day, M.J. Reed, P.G. Kasprzyk, A. Purohit, P.A. Foster. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t antigen transgenic mice. PLoS One. 2013;8:e80305.
30. P.A.Foster*, J.M. Day*, H.J. Tutill, F. Schmidlin, C.M. Sharland, J.D. Hargrave, N. Vicker, B.V.L. Potter, M.J. Reed, A. Purohit. STX2171, a 17b-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocr. Relat. Cancer. 2013;20:53-64.
27. P.A. Foster, Y.T. Ho, S.P. Newman, M.P. Leese, B.V. Potter, M.J. Reed, A. Purohit. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate surviving and XIAP expression in ovarian and prostate cancer cells. Anticancer Res. 2009; 29:3751-7.
26. J.M. Day, P.A. Foster, H.J. Tutill, S.P. Newman, Y.T. Ho, M.P. Leese, B.V.L. Potter, M.J. Potter, A. Purohit. BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br. J. Cancer. 2009; 100:476-86.
25. J.M. Day, A. Putohit, H.J. Tutill, P.A. Foster, L.W.L. Woo, B.V.L. Potter, M.J. Reed. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. Ann N Y Acad Sci. 2009; 1155:80-7.
24. J.M. Day, H.J. Tutill, P.A. Foster, H.V. Bailey, W.B. Heaton, C.M. Sharland, N. Vicker, B.V.L. Potter, A. Purohit, M.J. Reed. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3. Mol. Cell Endocrinol. 2009; 301:251-8.
23. P.A. Foster, S.K. Chander, S.P. Newman, L.W.L. Woo, O.B. Sutcliffe, C. Bubert, D. Zhou, S. Chen, B.V.L. Potter, M.J. Reed, A. Purohit. A new therapeutic strategy against hormone-dependent breast cancer: The pre-clinical development of a dual aromatase and sulfatase inhibitor (DASI). Clin. Cancer Res. 2008; 14: 6469-77.
22. S.L. Tagg, P.A.Foster, M.P.Leese, B.V.L. Potter, M.J. Reed, A. Purohit, S.P. Newman. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. Br. J. Cancer. 2008; 99:1842-8.
21. M.F.C. Parsons, P.A. Foster, S.K. Chander, R. Jhalli, S.P. Newman, M.P. Leese, B.V.L. Potter, A. Purohit, M.J. Reed. The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer. Br. J. Cancer. 2008; 99:1433-41.
19. P.A. Foster, S.K. Chander, M.F.C. Parsons, S.P. Newman, L.W.L.Woo, B.V.L.Potter, M.J. Reed, A. Purohit. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res. Treat. 2008; 111:129-38.
18. P.A. Foster, Y.T. Ho, S.P. Newman, P.G. Kasprzyk, M.P. Leese, B.V.L.Potter, M.J. Reed, A. Purohit. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res. Treat. 2008; 111:251-60.
17. P.A. Foster, L.W. Woo, B.V. Potter, M.J. Reed, A. Purohit. Steroid sulfatase inhibitors block the growth of hormone-dependent endometrial cancer xenografts: A potential new treatment. Endocinology. 2008; 149:4035-42.
16. P.A. Foster. Steroid metabolism in breast cancer. Minerva Endocrinologica. 2008;33:27-37.
15. P.A. Foster, S.P. Newman, M.P. Leese, S. Bernetiere, J. Camara, B.V. Potter, M.J. Reed, A. Purohit. A new micronised formulation of 2-methoxyestradiol-bis-sulphamate is therapeutically potent against breast cancer. Anti-cancer Res. 2008; 28:577-81.
14. P.A.Foster, C. Stengal, T. Ali, M.P.Leese, B.V.L. Potter, M.J. Reed, A. Purohit, S.P. Newman. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anti-cancer Res. 2008; 28:1483-91.
13. J.M. Day, P.A. Foster, H.J. Tutill, M.F.C. Parsons, S.K. Chander, G.M. Allan, H.R. Lawrence, N. Vicker, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo inhibition of estrone-stimulated tumor growth by STX1040; a 17b-hydroxysteroid dehydrogenase type 1 inhibitor with therapeutic potential. Int. J. Can. 2008;122:1931-1940.
12. S.P. Newman, P.A. Foster, C. Stengel, J.M. Day, Y.T. Ho, M.P. Leese, B.V.L. Potter, M.J. Reed, A. Purohit. The orally bioavailable microtubule disruptor, STX140, is efficacious in vitro and in vivo in Taxane resistant breast carcinoma cells. Clin. Can. Res. 2008; 14:597-606.
11. M.P. Leese, F.L. Jourdan, K. Gaukroger, M.F. Mahon, S.P. Newman, P.A. Foster, C. Stengal, S. Regis-Lydi, E Ferrandis, A.D. Fiore, G. De Simone, C.T. Supuran, A. Purohit, M.J. Reed, P.V.L. Potter. Structure-activity relationships of C-17 Cyano-substituted estratrienes as anticancer agents. J. Med. Chem. 2008; 51:1295-308.
10. L.W. Woo, D.S. Fischer, C.M. Sharland, M. Trusselle, P.A. Foster, S.K. Chander, A. Di Fiore, C.T. Supuran, G. De Simone, A. Purohit, M.J. Reed, B.V. Potter. Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modelling, and protein crystallography. Mol. Cancer Ther. 2008; 7: 2435-44.
9. S.P. Newman, P.A. Foster, Y.T. Ho, J.M. Day, B. Raobaikady, P.G. Kasprzyk, M.P. Leese, B.V. Potter, M.J. Reed, A. Purohit. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptos as therapy for hormone-independent prostate and breast cancer. Br. J. Cancer. 2007; 97, 1673-82.
8. S.K. Chander, P.A. Foster, M.P. Leese, S.P. Newman, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo inhibition of angiogenesis by sulfamoylated derivatives of 2-methoxyestradiol. Br. J. Cancer. 2007; 96, 1368-76.
7. P.A. Foster, S.P. Newman, S.K. Chander, C. Stengal, R. Jhalli, L.W.L. Woo, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin. Can. Res. 2006; 12, 5543-49.
6. R.S. Scotland, Cohen M, P.A. Foster, M. Lovell, A. Mathur, A. Ahluwalia, A.J. Hobbs. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. PNAS. 2005; 102, 14452-7.
5. A. Ahluwalia, P. Foster, R.A. Scotland, M.G. McLean, A. Mathur, M. Perretti, S. Moncada, A.J. Hobbs. Anti-inflammatory activity of soluble guanalyte cyclase: cyclic GMP-dependent down regulation of P-selectin expression and leukocyte recruitment. PNAS. 2004; 101, 1386-1391.
4. A. Hobbs, P.A. Foster, C. Prescott, R. Scotland, A. Ahluwalia. Natriuretic peptide receptor-C regulates blood flow and prevents myocardial ischemia/reperfusion injury: a novel cardioprotective role for endothelium-derived C-type natiuretic peptide. Circulation 2004; 101, 1231-5.
3. P.A. Foster, S.K.P. Costa, R. Postin, J.R.S. Hoult and S.D. Brain. Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor. FASEB. 2003; 17, 1703-5.
2. P.A. Foster, S. Wicks, M. Foster and S.D. Brain. Cellular pathology changes in rat skin following intradermal injection of nerve growth factor (NGF): neutrophil dependent and independent events. J. Pathol. 2002; 197, 245-255.
1. D.Q. Chu, M. Choy, P.A. Foster, T. Cao and S.D. Brain. A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin13-52 to modulate microvascular but not thermal hyperalgesia response. Br. J. Pharmacol. 2000; 130, 1589-1596.
- Foster, P.A. Newman, S.P. Woo, L.W.L. Reed, M.J. Purohit, A. Potter, B.V.L. Treatment of oestrogen dependent condition using dual aromatase-sulphatase inhibitors (DASI). Patent pending.
- Foster, P.A. Tagg, S.L. Newman, S.P. Reed, M.J. Purohit, A. Potter, B.V.L. Composition comprising a glycolytic inhibitor and an A-ring system comprising a sulphamate group for the treatment of cancer. U.S. Patent 20100144652. June 10, 2010.
- Potter, B.V.L. Reed, M.J. Woo, L.W.L. Purohit, A. Foster, P.A. Steroidal compounds as steroid sulphatase inhibitors. U.S. Patent 20090182000. July 16, 2009.